AACE's Disease State Networks (DSNs) provide pools of experts for AACE to draw upon to serve as physician liaisons, faculty, program editors for AACE educational programs and authors or reviewers for AACE clinical guidance documents.
Learn More
AACE Annual Meeting 2026 On-Demand
Starts 6/01/2026 | Expires 4/30/2027
Didn't make it to the AACE 2026 Annual Meeting? You can still access all the invaluable insights and groundbreaking discoveries with our on-demand session recordings.
Student/Resident/Fellow: $524 | Early Career Engaged Member: $524 | Engaged Member: $629
Informed Member: $839 | Non-member: $1,049
May 14–16, 2027
AACE Annual Meeting 2027, will take place Friday, May 14 to Sunday, May 16 at the Marriott Marquis San Diego Marina, in San Diego, CA.
The 2027 Call for Education Session Proposals is open now through July 20. Submit a proposal and your session may be chosen to be a part of the AACE 2027 Annual Meeting education program.
AACE Health Care Advocacy Webinar Series
Watch AACE’s complimentary 4-part on-demand webinar series—designed for endocrinologists and health care professionals—focused on strengthening your voice in health care advocacy. Learn how to drive impact at the institutional, state, and national levels, and gain critical insights on emerging issues like AI, team-based care, and telemedicine.
Starts 2/16/2026 | Expires 2/16/2028
AACE Self-Assessment Program (ASAP) Microlearning Volume 1 is designed for practicing clinical endocrinologists. This case-based microlearning course delivers high-yield clinical insights across the full spectrum of endocrine care. The program features six focused modules, each built around real-world patient cases.
Managing TED in Practice: Expanding the Endocrinologist’s Scope
Starts 10/6/2025 | Expires 10/6/2026
This complimentary on-demand webinar is designed to help clinicians create a path to diagnosis when encountering a patient with thyroid eye disease.
Paresthesia Muscle Spasms and Cramps: Unraveling the Hypocalcemia Puzzle in Hypoparathyroidism
Starts 10/13/2025 | Expires 10/13/2026
This complimentary on-demand webinar is designed to help clinicians create a path to diagnosis when encountering a patient with hypoparathyroidism.
AACE Rare Diseases and Hormone Disorders 2025: Pathways to Diagnosis
Starts 10/3/2025 | Expires 10/3/2026
Register for our complimentary Rare Diseases and Hormone Disorders webinar series covering rare endocrine conditions and hormone disorders including: thyroid eye disease, hypoparathyroidism, homozygous familial hypercholesterolemia, severe hypertriglyceridemia, congenital adrenal hyperplasia, and polycystic ovary syndrome.
AACE Clinical Guidance On-Demand
Didn't make it to the AACE 2025 Clinical Guidance Forum? Explore the newest AACE clinical guidance documents presented by the experts who created them and earn up to 5 CME/CE/MOC credits. This on-demand resource offers practical, case-based learning to help you implement evidence-based care in obesity, dyslipidemia, multiple endocrine neoplasia type 1, and menopause management.
April 22–24, 2026
Thank you to everyone who joined us in Las Vegas for AACE Annual Meeting 2026! We’re excited to announce that on-demand content is now available on the event platform, so you can revisit your favorite sessions and catch anything you may have missed.
Save the date and join us next year in San Diego, May 14–16, 2027, for another engaging and inspiring conference experience.
AACE Certificate: Thyroid Nodules
Starts: 7/28/2025 | Expires: 7/28/2027
This comprehensive online certificate program aims to provide endocrinologists and care team members with advanced training in the latest diagnostic and management strategies for thyroid conditions.
$295 | Informed Member - $235 | Engaged Member - $175 | Fellow, Resident, Student Member $115
This consensus statement provides information on novel minimally invasive therapeutic interventions for thyroid malignancies such as percutaneous ethanol injection and thermal ablation. The statement summarizes existing knowledge and provides guidance on indications, techniques, complications, and follow-ups for care of patients with benign and malignant thyroid lesions.
This consensus statement describes the Thyroid Nodule App (termed TNAPP), a novel interactive web-based tool that uses clinical, imaging, cytologic, and molecular marker data to guide clinical decision making to evaluate and manage thyroid nodules.
AvoMD, a software platform that brings clinical evidence into the workflow to help clinicians streamline decisions and save time, has partnered with AACE to integrate clinical guidance documents into the AvoMD platform.
The AACE Journey for Patients With Thyroid Disease is a reliable resource to help your patients better understand and manage their condition. Developed from our clinical guidance documents and reviewed by the Thyroid Cancer Survivors’ Association (ThyCa), it provides accurate, patient-centered information.
Read More
Watch our free on-demand webinar sponsored by Immunovant, Inc., to hear from clinical experts Mark Lupo, MD, founder and medical director of the Thyroid & Endocrine Center of Florida, and Giuseppe Barbesino, MD, of Massachusetts General Hospital, for a moderated discussion about the treatment landscape in Graves’ disease, which has remained largely unchanged for the last 70 years.
Read More
Graves’ disease and Thyroid Eye Disease (TED) are closely linked autoimmune conditions driven by antibodies targeting the thyroid-stimulating hormone receptor. This article, sponsored by Immunovant, explores the role of the thyroid-stimulating hormone receptor (TSHR), the current treatment landscapes for both Graves’ disease and thyroid eye disease (TED), and the promise of emerging therapies that target the underlying autoimmune cause.
Learn More
Myxedema coma and thyroid storm are rare thyroid emergencies with high mortality, requiring evidence of clinical decompensation in the setting of hypothyroidism or thyrotoxicosis for diagnosis. Urgent recognition, intensive supportive care, and rapid initiation of disease-specific therapy by a multidisciplinary team are critical for optimal outcomes.
This case emphasizes the need for vigilant monitoring of immune-related adverse events in patients receiving combination immune checkpoint inhibitors.
A PTH-guided Ca and calcitriol supplementation protocol significantly reduces post-TT hypocalcemia and related readmissions and may represent a useful approach in managing suitable candidates for outpatient TT
